ATRIVA THERAPEUTICS GMBH
Atriva Therapeutics is a clinical stage biopharmaceutical company developing host-targeting inhibitors against severe respiratory viral infections.
Indication:Influenza and other severe respiratory viral infections.
Year founded: 2015
Number of employees: 13
Financing/Partnering: Venture round EUR 35 Mn: EUR 16 Mn fresh funds to be used for PoC milestone in 2021, plus EUR 19 Mn for Ph IIb milestone in early 2023.
Atriva Therapeutics is a biopharmaceutical company pioneering the development of host-targeting antiviral therapies against different severe respiratory viral infections. The Company, located in Tübingen and Frankfurt, Germany, was founded in 2015 by a team of leading scientists in viral research and seasoned industry experts. Atriva’s lead drug candidate ATR-002 is a host-targeting MEK inhibitor, inhibiting viral replication in influenza and other respiratory infections, an area of high unmet medical need. ATR-002 is under clinical development and has successfully proven safety and tolerability in healthy subjects in a Phase I trial. The Company owns nine patent families with broad coverage related to the use of MEK inhibitors and other kinase inhibitors for anti-viral therapies.
New antiviral mode of action with high resistance barrier and broad activity.
Over EUR 700 Mn projected retail peak sales of ATRIVA’s MEK inhibitors in Influenza to be reached five years after first launch.
ATR-002 has successfully proven safety and tolerability in healthy subjects in a Phase I trial.
Dr. Rainer Lichtenberger